Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib

被引：240

作者：

Lacouture, Mario E. ^{[1
]}

Wu, Shenhong ^{[2
]}

Robert, Caroline ^{[3
]}

Atkins, Michael B. ^{[4
]}

Kong, Heidi H. ^{[5
]}

Guitart, Joan ^{[1
]}

Garbe, Claus ^{[6
]}

Hauschild, Axel ^{[7
]}

Puzanov, Igor ^{[8
]}

Alexandrescu, Doru T.

Anderson, Roger T. ^{[9
]}

Wood, Laura ^{[10
]}

Dutcher, Janice P. ^{[11
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA

[2] SUNY Stony Brook, Ctr Canc, Dept Med, Div Med Oncol, Stony Brook, NY 11794 USA

[3] Inst Gustave Roussy, Dermatol Unit, Villejuif, France

[4] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA

[5] NCI, Dermatol Branch, NIH, Bethesda, MD 20892 USA

[6] Univ Tubingen, Dept Dermatol, Tubingen, Germany

[7] Univ Kiel, Dept Dermatol, D-2300 Kiel, Germany

[8] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN USA

[9] Penn State Coll Med, Hershey, PA USA

[10] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA

[11] New York Med Coll, Ctr Comprehens Canc, Our Lady Mercy Med Ctr, Bronx, NY USA

来源：

ONCOLOGIST | 2008年 / 13卷 / 09期

关键词：

Sorafenib; Sunitinib; Hand-foot skin reaction; Forum consensus; Skin;

D O I：

10.1634/theoncologist.2008-0131

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The multitargeted kinase inhibitors (MKIs) sorafenib and sunitinib have shown benefit in patients with renal cell carcinoma, hepatocellular carcinoma (sorafenib), and gastrointestinal stromal tumor (sunitinib). Their efficacy in other malignancies is currently being investigated because of their broad range of activity. The effectiveness of these drugs is somewhat diminished by the development of a variety of toxicities, most notably hand-foot skin reaction (HFSR). Although HFSR does not appear to directly affect survival, it can impact quality of life and lead to MKI dose modification or interruption, potentially limiting the antitumor effect. Currently, no standard guidelines exist for the prevention and management of MKI-associated HFSR. To address this issue, an international, interdisciplinary panel of experts gathered in January 2008 to discuss and evaluate the best-practice management of these reactions. Based on these proceedings, recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy. The Oncologist 2008; 13: 1001-1011

引用

页码：1001 / 1011

页数：11

共 58 条

[1] Kinase inhibition with BAY 43-9006 n renal cell carcinoma [J].

Ahmad, T ;

Eisen, T .

CLINICAL CANCER RESEARCH, 2004, 10 (18) :6388S-6392S

[2] Development and validation of a quality of life instrument for cutaneous diseases [J].

Anderson, RT ;

Rajagopalan, R .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (01) :41-50

[3]

[Anonymous], Dictionary of cancer terms

[4] HUMAN KERATINOCYTES ARE A MAJOR SOURCE OF CUTANEOUS PLATELET-DERIVED GROWTH-FACTOR [J].

ANSEL, JC ;

TIESMAN, JP ;

OLERUD, JE ;

KRUEGER, JG ;

KRANE, JF ;

TARA, DC ;

SHIPLEY, GD ;

GILBERTSON, D ;

USUI, ML ;

HART, CE .

JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (02) :671-678

[5] THE MEASUREMENT OF INSTRUMENTAL ADL - CONTENT VALIDITY AND CONSTRUCT-VALIDITY [J].

AVLUND, K ;

SCHULTZLARSEN, K ;

KREINER, S .

AGING-CLINICAL AND EXPERIMENTAL RESEARCH, 1993, 5 (05) :371-383

[6]

Azad NS, 2007, J CLIN ONCOL, V25

[7]

*BAYER PHARM CORP, 2007, NEX PACK INS

[8] Localized palmar-plantar epidermal hyperplasia: A previously undefined dermatologic toxicity to sorafenib [J].

Beldner, Matthew ;

Jacobson, Michael ;

Burges, Gene E. ;

Dewaay, Deborah ;

Maize, John C., Jr. ;

Chaudhary, Uzair B. .

ONCOLOGIST, 2007, 12 (10) :1178-1182

[9] Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma [J].

Bhojani, Naeem ;

Jeldres, Claudio ;

Patard, Jean-Jacques ;

Perrotte, Paul ;

Suardi, Nazareno ;

Hutterer, Georg ;

Patenaude, Francois ;

Oudard, Stephane ;

Karakiewicz, Pierre I. .

EUROPEAN UROLOGY, 2008, 53 (05) :917-930

[10] Protein kinase inhibitors in the treatment of renal cell carcinoma:: sorafenib [J].

Bracarda, S. ;

Caserta, C. ;

Sordini, L. ;

Rossi, M. ;

Hamzay, A. ;

Crino, L. .

ANNALS OF ONCOLOGY, 2007, 18 :22-25

← 1 2 3 4 5 6 →